Filtered By:
Drug: Simvastatin

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 124 results found since Jan 2013.

No proof Earl Grey can fight heart disease
Conclusion This animal experiment indicated that the bergamot extract HMGF may have cholesterol-lowering effects similar to that of the commonly used statin, simvastatin, when given to mice with high cholesterol levels that were fed high cholesterol diets for three weeks. The main limitation of the study was that none of the research involved humans. Therefore, it is not possible to say the bergamot extract would work the same way in humans, unless directly tested. Furthermore, this rat study tested a pure extract rather than tea containing the extract, the effects of which may be different. For instance, taking milk in te...
Source: NHS News Feed - April 1, 2014 Category: Consumer Health News Tags: Heart/lungs Medication Food/diet Source Type: news

The inhibitory effect of simvastatin and aspirin on histamine responsiveness in human vascular endothelial cells
Statins and aspirin deliver well-established cardiovascular benefits resulting in their increased use as combined polypills to decrease risk of stroke and heart disease. However, the direct endothelial effect of combined statin/aspirin cotreatment remains unclear. Histamine is an inflammatory mediator that increases vascular permeability, and so we examined the effect of treating human umbilical vein endothelial cells (HUVECs) for 24 h with 1 μM simvastatin and 100 μM aspirin on histamine responsiveness. Subsequent histamine (1 μM) challenge increased intracellular calcium (Ca2+i) concentration, an effect that was...
Source: AJP: Cell Physiology - April 1, 2014 Category: Cytology Authors: Absi, M., Bruce, J. I., Ward, D. T. Tags: ARTICLES Source Type: research

Brain proteomics identifies possible simvastatin targets in acute phase of stroke in a rat embolic model
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - March 24, 2014 Category: Neurology Authors: Mireia Campos‐Martorell, Nelida Salvador, Marta Monge, Francesc Canals, Lidia García‐Bonilla, Mar Hernández‐Guillamon, María Irene Ayuso, Pilar Chacón, Anna Rosell, Alberto Alcazar, Joan Montaner Tags: Original Article Source Type: research

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial.
CONCLUSIONSIn the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality. PMID: 24595629 [PubMed - as supplied by publisher]
Source: Diabetes Care - March 4, 2014 Category: Endocrinology Authors: Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Venkat Narayan KM, Riddle MC, Sood A, Goff DC Tags: Diabetes Care Source Type: research

NICE publishes new draft guidelines on statins use
"Millions more people should be put on cholesterol-lowering statin drugs," BBC News reports. Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended that the drugs should be given to people with an estimated 1 in 10 or more risk of cardiovascular disease (CVD), which includes conditions such as heart disease and stroke. Statins are medicines that can help lower rates of low-density lipoprotein (LDL) cholesterol (so-called "bad" cholesterol) in the blood. High rates of LDL cholesterol can lead to hardening of the arteries, a risk factor for CVDs. At present,...
Source: NHS News Feed - February 12, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL)
Clinical trials have not provided evidence for a role of statin therapy in reducing aortic valve stenosis (AVS) severity in patients with documented AVS. However, whether statin therapy could prevent the onset of AVS is unknown. Our objectives were (1) to compare the incidence rates of AVS among patients treated with high-dose versus usual-dose statin or placebo and (2) to identify clinical risk factors associated with the development of AVS. We conducted post hoc analyses in 23,508 participants from 3 large-scale multicenter atorvastatin randomized blinded clinical trials: Treating to New Targets, the Incremental Decrease...
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Benoit J. Arsenault, S. Matthijs Boekholdt, Samia Mora, David A. DeMicco, Weihang Bao, Jean-Claude Tardif, Pierre Amarenco, Terje Pedersen, Philip Barter, David D. Waters Tags: Valvular Heart Disease Source Type: research

The Inhibitory Effect of Simvastatin and Aspirin on Histamine Responsiveness in Human Vascular Endothelial Cells.
Abstract Statins and aspirin deliver well-established cardiovascular benefits resulting in their increased use as combined polypills to decrease risk of stroke and heart disease. However, the direct endothelial effect of combined statin/aspirin cotreatment remains unclear. Histamine is an inflammatory mediator that increases vascular permeability and so we examined the effect of treating human umbilical vein endothelial cells (HUVECs) for 24-hours with 1μM simvastatin and 100μM aspirin on histamine responsiveness. Subsequent histamine (1μM) challenge increased Ca(2+)i concentration, an effect that was significa...
Source: Am J Physiol Cell Ph... - January 29, 2014 Category: Cytology Authors: Absi M, Bruce JI, Ward DT Tags: Am J Physiol Cell Physiol Source Type: research

Dose-Related Effects of Statins on Symptomatic Intracerebral Hemorrhage and Outcome After Thrombolysis for Ischemic Stroke Clinical Sciences
Conclusions— We observed an association between increasing dose of statin use and risk of sICH after intravenous thrombolysis. Nevertheless, there was an overall beneficial effect of previous statin use on favorable 3-month outcome.
Source: Stroke - January 27, 2014 Category: Neurology Authors: Scheitz, J. F., Seiffge, D. J., Tutuncu, S., Gensicke, H., Audebert, H. J., Bonati, L. H., Fiebach, J. B., Tranka, C., Lyrer, P. A., Endres, M., Engelter, S. T., Nolte, C. H. Tags: Other Treatment, Thrombolysis Clinical Sciences Source Type: research

Relationship of Lipoproteins to Cardiovascular Events The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.BackgroundDuring a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.MethodsSubjects taking simvastatin and/or ez...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 14, 2013 Category: Cardiology Source Type: research

Combining Statins with Tissue Plasminogen Activator Treatment After Experimental and Human Stroke: A Safety Study on Hemorrhagic Transformation.
CONCLUSION: This study consistently confirms that the use of statins does not increase HT rates and severity when is combined with tPA administration. PMID: 24118905 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - October 14, 2013 Category: Neuroscience Authors: Campos M, García-Bonilla L, Hernández-Guillamon M, Barceló V, Morancho A, Quintana M, Rubiera M, Rosell A, Montaner J Tags: CNS Neurosci Ther Source Type: research

Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) Trial Major Clinical Trials
Conclusions— Although there were numerically more ischemic strokes with addition of ERN to simvastatin that reached nominal significance, the number was small, and multivariable analysis accounting for known risk factors did not support a significant association between niacin and ischemic stroke risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00120289.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Teo, K. K., Goldstein, L. B., Chaitman, B. R., Grant, S., Weintraub, W. S., Anderson, D. C., Sila, C. A., Cruz-Flores, S., Padley, R. J., Kostuk, W. J., Boden, W. E., on behalf of the AIM-HIGH Investigators Tags: Secondary prevention, Risk Factors, Acute Cerebral Infarction, Other Stroke Treatment - Medical Major Clinical Trials Source Type: research

Statin use linked to small increase in cataracts risk
Conclusion This research using a large cohort of people from a military healthcare system finds that overall, use of statins for over 90 days was associated with a slight increase in a person’s risk of developing cataracts. Further analyses suggested that the risk was higher among people who did not have any additional diseases. From this the researchers suggest that risk may be higher when statins are given for what is called primary prevention, i.e. given to people with risk factors for cardiovascular disease but who have not yet suffered any cardiovascular disease events such as a heart attack or stroke. The study h...
Source: NHS News Feed - September 20, 2013 Category: Consumer Health News Tags: Medication Older people Heart/lungs Source Type: news

Relationship of Lipoproteins to Cardiovascular Events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.Background: During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.Methods: Subjects taking simvastatin and/o...
Source: Journal of the American College of Cardiology - August 2, 2013 Category: Cardiology Authors: John R. Guyton, April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg, Moti L. Kashyap, Santica M. Marcovina, Stephen D. Nash, Kevin D. O'Brien, William S. Weintraub, Ping Xu, Xue-Qiao Zhao, William E. Boden Tags: Cardiometabolic Risk Source Type: research

RApid Primary care Initiation of Drug treatment for Transient Ischaemic Attack (RAPID-TIA): study protocol for a pilot randomised controlled trial
DiscussionThis pilot study will be used to estimate key parameters that are needed to design the main study and to estimate the accuracy of primary care diagnosis of TIA. The planned follow-on trial will have important implications for the initial management of people with suspected TIA.Trial registration: ISRCTN62019087
Source: Trials - July 2, 2013 Category: Journals (General) Authors: Duncan EdwardsKate FletcherRachel DellerRichard McManusDaniel LassersonMatthew GilesDon SimsJohn NorrieGraham McGuireSimon CohnFiona WhittleVicky HobbsChristopher WeirJonathan Mant Source Type: research

Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: The simvastatin and ezetimibe in aortic stenosis study
Abstract: Background: Left atrial (LA) size and function change with chronically increased left ventricular (LV) filling pressures. It remains unclear whether these variations in LA parameters can predict new-onset atrial fibrillation (AF) in asymptomatic patients with aortic stenosis (AS).Methods: Data were obtained in asymptomatic patients with mild-to-moderate AS (2.5≤ transaortic Doppler velocity ≤4.0m/s), preserved LV ejection fraction (EF), no previous AF, and were enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis study. Peak-aortic velocity, LAmax volume & LAmin volume were measured by echocardiograph...
Source: International Journal of Cardiology - February 18, 2013 Category: Cardiology Authors: Casper N. Bang, Morten Dalsgaard, Anders M. Greve, Lars Køber, Christa Gohlke-Baerwolf, Simon Ray, Anne B. Rossebø, Kenneth Egstrup, Kristian Wachtell Tags: Original Articles Source Type: research